Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

Autor: Raffi Tachdjian, D. Soteres, Mustafa Shennak, Lawrence B. Schwartz, William R. Lumry, Selina Gierer, H. Henry Li, William H. Yang, Aleena Banerji, Jacques Hébert, Markus Magerl, Marcus Maurer, Hilary Longhurst, Timothy J. Craig, Andrew M. Smith, Syed M. Rehman, Jonathan A. Bernstein, Mark Davis-Lorton, H. James Wedner, Inmaculada Martinez-Saguer, Andrea Zanichelli, Marco Cicardi, Petra Staubach, Ralph Shapiro, John Anderson, Michael E. Manning, Rafael Zaragoza-Urdaz, Douglas T. Johnston, Marc A. Riedl, Jovanna Baptista, Wolfram Nothaft, Paula J. Busse, Joshua J. Jacobs, Jennifer Schranz, Bruce L. Zuraw

Publikováno v: JAMA. 320(20)

Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a842971a9ec37114d35e794b0649508c
https://pubmed.ncbi.nlm.nih.gov/31012909

Reply

Autor: Richard Sinert, Phillip Levy, Jonathan A. Bernstein, Richard Body, Marco L.A. Sivilotti, Joseph Moellman, Jennifer Schranz, Jovanna Baptista, Alan Kimura, Wolfram Nothaft

Publikováno v: Sinert, R, Levy, P, Bernstein, J A, Body, R, Sivilotti, M L A, Moellman, J, Schranz, J, Baptista, J, Kimura, A, Nothaft, W & CAMEO study group 2017, ' Reply ', The journal of allergy and clinical immunology. In practice, vol. 5, no. 6, pp. 1803-1804 . https://doi.org/10.1016/j.jaip.2017.07.040

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d82188967fcea2deb96931fa78e7c85
https://doi.org/10.1016/j.jaip.2017.07.040

An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UVB-inflamed and normal skin

Autor: Charles Locke, Peter W. Reeh, W. Rachel Duan, Ahmed A. Othman, Klaus Schaffler, Connie R. Faltynek, Wolfram Nothaft, Andrea E. Best

Publikováno v: British Journal of Clinical Pharmacology. 75:404-414

Aims Laser (radiant-heat) evoked potentials (LEPs) from vertex-EEG peak-to-peak (PtP) amplitude were used to determine acute antinociceptive/antihyperalgesic efficacy of ABT-102, a novel TRPV1 antagonist efficacious in preclinical pain models, compar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3512370321050a2147fbafccf5e6a4c
https://doi.org/10.1111/j.1365-2125.2012.04377.x

Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain

Autor: Michael C. Rowbotham, Y. Pritchett, Andrea E. Best, W. Rachel Duan, Armen Arslanian, Qian Zhou, Brett R. Stacey, Wolfram Nothaft

Publikováno v: Pain. 153:862-868

Preclinical and clinical studies suggest that neuronal nicotinic receptor (NNR) agonists may be a novel and effective therapy for numerous painful conditions. Analgesic efficacy and safety of the highly selective α(4)β(2) NNR agonist ABT-894 was ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d95b55e8b46dcaea3779378d1d15831
https://doi.org/10.1016/j.pain.2012.01.009

Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial

Autor: Wei Liu, Romà Solà, W.R. Duan, Charles Locke, Jordi Serra, Wolfram Nothaft

Publikováno v: Pain. 156(11)

T-type calcium channels are a potential novel target for treatment of neuropathic pain such as painful diabetic neuropathy. ABT-639 is a peripherally acting highly selective T-type Cav3.2 calcium channel blocker that has demonstrated analgesic effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a026eadb95b2c6e1a683d99619c77d69
https://pubmed.ncbi.nlm.nih.gov/26035253